CollPlant Biotechnologies Ltd. (CLGN)
| Market Cap | 171.31M |
| Revenue (ttm) | 19.90M |
| Net Income (ttm) | 4.88M |
| Shares Out | 10.26M |
| EPS (ttm) | 0.51 |
| PE Ratio | 33.35 |
| Forward PE | 8.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,972 |
| Open | 16.65 |
| Previous Close | 16.70 |
| Day's Range | 16.65 - 17.20 |
| 52-Week Range | 15.98 - 23.49 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 13.02 (-22.7%) |
| Est. Earnings Date | n/a |
About CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissu...
Financial Performance
In 2020, CLGN's revenue was $6.14 million, an increase of 164.75% compared to the previous year's $2.32 million. Losses were -$5.77 million, -48.28% less than in 2019.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CLGN stock is "Buy" and the 12-month stock price forecast is 13.02.
News
CollPlant CEO Yehiel Tal elected to the Board of Directors of the International Society for Biofabrication (ISBF)
REHOVOT, Israel, Sept. 9, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ ...
CollPlant To Present at the H.C. Wainwright Annual Global Investment Conference in September
REHOVOT, Israel, Sept. 7, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ ...
CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ m...
Recap: CollPlant Biotechnologies Q2 Earnings
Shares of CollPlant Biotechnologies (NASDAQ:CLGN) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 25.00% year over year to ($0.25), which missed the estim...
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ m...
CollPlant Biotechnologies to Present on the Use of Collagen BioInk as a Platform for 3D Bioprinting of Tissues and Or...
REHOVOT, Israel, Aug. 16, 2021 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ ma...
Why 3D Systems, CollPlant BioTechnologies, and Stratasys Stocks Soared Today
Five months ago, 3D Systems promised to expand into the "nascent industry" of printing entire human body parts. Today, it's doing just that.
CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs
REHOVOT, Israel, June 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced today the uplisting of its ordinary shares to the Nasdaq Global Select Ma...
CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million
REHOVOT, Israel, May 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the first quarter ended March 31, 2021 and pr...
CollPlant Announces Uplisting to the Nasdaq Global Market® and Transition to Trading of Ordinary Shares Instead of ADSs
REHOVOT, Israel, May 25, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced that its ordinary shares have been approved for trading on the Nasdaq Glo...
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $14.68 in the latest trading session, marking a +1.91% move from the prior day.
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Stock Moves -0.22%: What You Should Know
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.77 in the latest trading session, marking a -0.22% move from the prior day.
CollPlant (CLGN) to Report Q1 Earnings: What's in the Cards?
CollPlant (CLGN) is set to report earnings and revenues, and provide product updates when it releases first-quarter 2021 results.
Is CollPlant Biotechnologies Ltd. Sponsored (CLGN) Stock Outpacing Its Medical Peers This Year?
Is (CLGN) Outperforming Other Medical Stocks This Year?
CollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors
REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increas...
CollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2020
REHOVOT, Israel, March 26, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and p...
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Dips More Than Broader Markets: What You Should Know
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $12.26 in the latest trading session, marking a -1.84% move from the prior day.
Has CollPlant Biotechnologies Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?
Is (CLGN) Outperforming Other Medical Stocks This Year?
6 Beaten Down Stocks with Solid Growth Potential
Are you going to sit around to try and price a bottom or are you going to grab stocks that look obviously cheap today?
CollPlant To Present at the H.C. Wainwright Global Life Sciences Conference
REHOVOT, Israel, March 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will p...
Termination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants
REHOVOT, Israel, Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on February 24, 2021 it received a notice fro...
CollPlant Issues Letter to Shareholders
REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders. Dear share...
CollPlant Announces Closing of $35.0 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has closed the previously announced registered direct offering for the purchase and sa...
Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today
Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-...
CollPlant Announces $35.0 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has entered into definitive agreements with several healthcare-focused and other insti...